JOP20180057A1 - مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 - Google Patents

مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Info

Publication number
JOP20180057A1
JOP20180057A1 JOP/2018/0057A JOP20180057A JOP20180057A1 JO P20180057 A1 JOP20180057 A1 JO P20180057A1 JO P20180057 A JOP20180057 A JO P20180057A JO P20180057 A1 JOP20180057 A1 JO P20180057A1
Authority
JO
Jordan
Prior art keywords
tetrahydropyridopyrazine
gpr6
modulators
compound
formula
Prior art date
Application number
JOP/2018/0057A
Other languages
English (en)
Inventor
Todd Macklin
Jason W Brown
Stephen Hitchcock
Shota Kikuchi
Kristin Schleicher
Maria Hopkins
Holger Monenschein
Holly Reichard
Huikai Sun
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of JOP20180057A1 publication Critical patent/JOP20180057A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتم إعداد مركب بالصيغة 1، وملح مقبول صيدليا pharmaceutically acceptable salt منه. يتعلق هذا الطلب أيضا بمواد materials وطرق methods لتحضير المركب الذي بالصيغة 1، ويتعلق بتركيبات صيدلية pharmaceutical compositions والتي تحتوي على هذا المركب، والاستخدام في علاج diseases أمراض، اضطرابات disorders، وحالات conditions ترتبط بـ GPR6.
JOP/2018/0057A 2017-06-15 2017-06-15 مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 JOP20180057A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US201862672261P 2018-05-16 2018-05-16

Publications (1)

Publication Number Publication Date
JOP20180057A1 true JOP20180057A1 (ar) 2019-01-30

Family

ID=64656005

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0057A JOP20180057A1 (ar) 2017-06-15 2017-06-15 مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Country Status (16)

Country Link
US (1) US10406157B2 (ar)
EP (1) EP3638673A4 (ar)
JP (1) JP7460369B2 (ar)
KR (1) KR20200014796A (ar)
CN (1) CN110730781B (ar)
AU (1) AU2018285677B2 (ar)
BR (1) BR112019026430A2 (ar)
CA (1) CA3067032A1 (ar)
CO (1) CO2019015086A2 (ar)
IL (1) IL271332B2 (ar)
JO (1) JOP20180057A1 (ar)
MX (1) MX2019014940A (ar)
PH (1) PH12019502792A1 (ar)
SG (1) SG11201912149WA (ar)
TW (1) TWI775874B (ar)
WO (1) WO2018232202A1 (ar)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6
JP6526034B2 (ja) * 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター

Also Published As

Publication number Publication date
US10406157B2 (en) 2019-09-10
US20180360831A1 (en) 2018-12-20
CN110730781A (zh) 2020-01-24
EP3638673A1 (en) 2020-04-22
RU2019144408A (ru) 2021-07-15
JP2022188199A (ja) 2022-12-20
IL271332A (en) 2020-01-30
WO2018232202A1 (en) 2018-12-20
CN110730781B (zh) 2023-05-05
SG11201912149WA (en) 2020-01-30
JP2020523287A (ja) 2020-08-06
PH12019502792A1 (en) 2020-09-14
JP7460369B2 (ja) 2024-04-02
CO2019015086A2 (es) 2020-04-13
IL271332B2 (en) 2023-02-01
MX2019014940A (es) 2020-02-19
CA3067032A1 (en) 2018-12-20
AU2018285677A1 (en) 2019-12-19
IL271332B (en) 2022-10-01
TWI775874B (zh) 2022-09-01
EP3638673A4 (en) 2021-03-24
AU2018285677B2 (en) 2022-07-14
TW201906844A (zh) 2019-02-16
BR112019026430A2 (pt) 2020-07-14
RU2019144408A3 (ar) 2021-09-07
KR20200014796A (ko) 2020-02-11

Similar Documents

Publication Publication Date Title
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018501068A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2023001876A (es) Derivados de rapamicina.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ747259A (en) Soluble c5ar antagonists
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
EP4316591A3 (en) Oxysterols and methods of use thereof
AU2018253590A1 (en) Imidazopyridazine compounds
AU2018277520A1 (en) 6-5 fused rings as C5a inhibitors
TN2017000144A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
WO2019175799A3 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
MX2017016939A (es) Novedosas antagonistas 5-ht2.